Boast­ing new dis­cov­er­ies from Xtan­di, Er­lea­da in­ven­tors, ORIC pitch­es $86M IPO on can­cer drugs tar­get­ed at re­sis­tance

Months af­ter kick­ing off Phase Ib tri­als, a group of sea­soned can­cer drug de­vel­op­ers out of the Bay Area have filed for an $86 mil­lion IPO in an­tic­i­pa­tion of a pre­lim­i­nary look on whether their glu­co­cor­ti­coid re­cep­tor an­tag­o­nist works against prostate can­cer and oth­er sol­id tu­mors.

As ORIC Phar­ma­ceu­ti­cals’ name — which is ac­tu­al­ly an acronym — sug­gests, the com­pa­ny wants to “over­come re­sis­tance in can­cer.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.